Compare Paychex, Inc. (PAYX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Smith & Nephew plc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $43.33B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Paychex, Inc. is far larger — about 3.7× Smith & Nephew plc's market cap, and Paychex, Inc. pays the higher dividend (3.91%). Which is the better fit depends on your goals.
| PAYX | SNN | |
|---|---|---|
Market Cap | $43.33B | $11.63B |
Sector | Industrials | Health |
52-Week High | $135.46 | $38.53 |
52-Week Low | $85.57 | $27.80 |
Enterprise Value | $46.81B | $14.66B |
Dividend Yield | 3.91% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% over the past day, near the consensus price target of $118.17. The stock shows strong profitability with a 27.03% net income margin and 44.77% ROE, though valuation ratios like a P/E of 24.89 and P/S of 6.73 are elevated. Recent quarters have consistently beaten EPS estimates, and the company is advancing its AI-driven WISE platform to enhance payroll efficiency. Technical indicators are mixed, with a bearish moving average signal but an oversold RSI suggesting potential near-term support.
The outlook for PAYX is cautiously optimistic, supported by steady earnings beats and strategic AI integration, but high valuation and mixed analyst sentiment pose risks. Investment opportunity lies in continued execution on margin expansion and market share gains in HR solutions, while key risks include competitive pressures and economic sensitivity affecting small business clients.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
